Yumiko Wada

Summary

Publications

  1. pmc Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis
    Yumiko Wada
    Synta Pharmaceuticals Corp, Lexington, Massachusetts, United States of America
    PLoS ONE 7:e35069. 2012
  2. ncbi request reprint Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor
    Yumiko Wada
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Blood 109:1156-64. 2007
  3. pmc Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis
    Hiroshi Keino
    Department of Ophthalmology, Kyorin University School of Medicine, 6 20 2 Shinkawa, Mitaka, Tokyo, 181 8611 Japan
    Arthritis Res Ther 10:R122. 2008
  4. doi request reprint Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib
    Jaime Acquaviva
    Synta Pharmaceuticals, Corp, Lexington, MA 02421, USA
    Mol Cancer Ther 11:2633-43. 2012
  5. pmc Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
    David A Proia
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Invest New Drugs 30:2201-9. 2012
  6. doi request reprint The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells
    Masazumi Nagai
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Free Radic Biol Med 52:2142-50. 2012
  7. pmc Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression
    Suqin He
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Int J Oncol 42:35-43. 2013
  8. doi request reprint Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy
    Weiwen Ying
    Synta Pharmaceuticals Corp, 45 Hartwell Avenue, Lexington, MA 02421, USA
    Mol Cancer Ther 11:475-84. 2012

Collaborators

  • David A Proia
  • Yuan Liu
  • James G Krueger
  • Suqin He
  • Jim Sang
  • Jaime Acquaviva
  • Manuel Sequeira
  • Donald L Smith
  • Chaohua Zhang
  • Julie C Friedland
  • Luisa Shin Ogawa
  • James Barsoum
  • Takayo Inoue
  • Ronald K Blackman
  • Keizo Koya
  • Weiwen Ying
  • Masazumi Nagai
  • Hiroshi Keino
  • Ayesha A Shafi
  • Nancy L Weigel
  • John Chu
  • Britte C Beaudette-Zlatanova
  • Lijun Sun
  • Kevin P Foley
  • Dan Zhou
  • Zhenjian Du
  • Nha H Vo
  • Dinesh Chimmanamada
  • Shuxia Ye
  • Noriaki Tatsuta
  • Rongzhen Lu
  • Jamie Acquaviva
  • Mamoru Niikura
  • Yasuhiko Sato
  • Takayo Watanabe
  • Annabelle A Okada

Detail Information

Publications8

  1. pmc Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis
    Yumiko Wada
    Synta Pharmaceuticals Corp, Lexington, Massachusetts, United States of America
    PLoS ONE 7:e35069. 2012
    ..This study demonstrates the immunomodulatory activity of apilimod and provides clinical evidence supporting the inhibition of IL-12/IL-23 synthesis for the treatment of T(H)1- and T(H)17-mediated inflammatory diseases...
  2. ncbi request reprint Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor
    Yumiko Wada
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Blood 109:1156-64. 2007
    ..STA-5326 currently is being evaluated in phase 2 clinical trials in patients with Crohn disease and rheumatoid arthritis...
  3. pmc Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis
    Hiroshi Keino
    Department of Ophthalmology, Kyorin University School of Medicine, 6 20 2 Shinkawa, Mitaka, Tokyo, 181 8611 Japan
    Arthritis Res Ther 10:R122. 2008
    ..The purpose of this study was to determine if oral administration of the interleukin (IL) 12/IL-23 inhibitor, STA-5326, is effective in experimental autoimmune uveoretinitis (EAU)...
  4. doi request reprint Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib
    Jaime Acquaviva
    Synta Pharmaceuticals, Corp, Lexington, MA 02421, USA
    Mol Cancer Ther 11:2633-43. 2012
    ..Taken together, these data underscore the promise of ganetespib as a single-agent or combination treatment in KRAS-driven lung tumors...
  5. pmc Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
    David A Proia
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Invest New Drugs 30:2201-9. 2012
    ..Taken together, these findings provide preclinical evidence for the use of this combination to treat patients with advanced NSCLC...
  6. doi request reprint The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells
    Masazumi Nagai
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Free Radic Biol Med 52:2142-50. 2012
    ..Together these findings highlight a unique mechanism of action with important implications for cancer therapy...
  7. pmc Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression
    Suqin He
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Int J Oncol 42:35-43. 2013
    ..Together these data suggest that further investigation of ganetespib as a new therapeutic treatment for prostate cancer patients is warranted...
  8. doi request reprint Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy
    Weiwen Ying
    Synta Pharmaceuticals Corp, 45 Hartwell Avenue, Lexington, MA 02421, USA
    Mol Cancer Ther 11:475-84. 2012
    ....